

**Research Paper**

*Afr. J. Traditional,
Complementary and
Alternative Medicines*
www.africanethnomedicines.net

ISSN 0189-6016©2008***IN VIVO* SCREENING OF ANTIMALARIAL ACTIVITY OF *ACACIA MELLIFERA* (BENTH) (LEGUMINOSAE) ON *PLASMODIUM BERGHEI* IN MICE****Charles Mutai ^{1*}, Geoffrey Rukunga ¹, Constatinos Vagias ² and Vassilios Roussis ².**¹Kenya Medical Research Institute, P.O Box 548540-00200, Nairobi, Kenya.²University of Athens, Department of pharmacy, Division of phamacognosy and Chemistry of Natural Products, Panepistimioupolis Zografou, Athens 15771, Greece.***E-mail:** cmutai@kemri.org**Abstract**

The activities of total extracts and lupane triterpenes, isolated from the stem bark of *Acacia mellifera*, were evaluated against *Plasmodium berghei* strain ANKA in a female Swiss mouse model. Five isolated compounds and the crude extracts were evaluated for antimalarial activity and Quinine hydrochloride was used as a positive control. Only betulin and the methanolic extract produced considerable antimalarial activity in mice infected with *P. berghei* parasites. This study demonstrated the presence of bioactive agents in *Acacia mellifera*.

Key words: *Acacia mellifera*, lupane triterpenes, Antimalarial activity, mice**Introduction**

Malaria is a disease of immense public importance. Available data suggest that there are 200-300 million cases, with more than two million deaths each year (Krogstad et al, 1990) out of which one million is from the African continent alone [Daniel et al, 1988]. Chloroquine, a 4-aminoquinolone, has been the mainstay of malaria chemotherapy for almost 50 years now. This is because of its rapid onset of action, low toxicity and, almost low expense. It has remained the cheapest and most widely used antimalarial drug in parts of Africa (Daniel et al, 1988; Adubofour et al, 1992; WHO, 1984). Chloroquine-resistant *Plasmodium falciparum* has been reported in parts of Africa (Le Bras et al, 1986; Sansonetti et al, 1985). Resistance to chloroquine developed in Southeast Asia and South America at the end of the 1950s and in Africa by the late 1970s (Wharhurst, 2001). Since the emergence of chloroquine resistant strains of *P. falciparum*, the rate of resistance has been increasing and limiting adequate treatment of malaria [Peters, 1998; Neequaye et al, 1986]. Consequently, there is an urgent global need to isolate from natural sources new classes of antimalarial compounds. A natural product artemisinin has previously shown excellent efficacy as non-alkaloidal, fast acting drug effective for chemotherapy against malaria (Ziffer et al, 1997). *Acacia mellifera* has been reported to be used to treat malaria (Kokwaro, 1976] and used locally in Kenya traditional medicine.

As part of the search for new natural product for the treatment of various diseases (Mutai et al, 2004), we carried out a screening procedure to test *A. mellifera* total extract for the ability to treat malaria. On further purification of total extracts, pure metabolites were obtained and were also further investigated (Mutai et al, 2004].

Materials and Methods**Plant collection and Extraction**

Stem bark of *A. mellifera* was collected in January 2000, from at Machakos Kenya. The plant was authenticated at the East Africa Herbarium, National Museum of Kenya and a voucher specimen deposited at the same Institute in Nairobi, (Voucher number ChM-I). Air-dried, powdered stem bark of *A. mellifera* (2.25 kg) was

extracted at room temperature, successively with dichloromethane (CH_2Cl_2) and methanol (MeOH) for 48 h each. The solvents were removed *in vacuo* to yield CH_2Cl_2 extract and MeOH extract. The extracts were each subjected separately to silica gel column chromatography eluted with a mixture of EtOAc and MeOH of increasing polarity. The purity of fractions was monitored using TLC. Identical fractions were pooled together. Further purification was done by rechromatography using gravity columns and then later subjected to HPLC. Six pure compounds namely: Acetylated epicatechin (4 β -8) catechin from methanol extract and five lupan types (Figure 1): 3-(Z)-*trans* coumaroylbetulin, 3-(E)-*cis* coumaroylbetulin, 30-hydroxylup-20 (29)-en -3-one, Betulin and Lupeol from dichloromethane extract were isolated and their structures elucidated using spectroscopic methods.




Figure 1: Isolated compounds

Parasites and Antimalarial Tests

The *Plasmodium berghei* strain ANKA used in the study was obtained from Kenya Medical Research Institute (KEMRI). The parasite strain was propagated in mice and maintained by serial passage of infected erythrocytes.

The antimalarial activity of the extracts or pure compounds was evaluated by the 4-day suppressive test described by Peters et al (1970, 1982). Adult female Swiss mice weighing 18-21 g were inoculated through i.p. route with 1×10^7 *P. berghei*-infected erythrocytes. The mice were randomly divided into groups of five animals per cage and treated during 4 consecutive days with daily doses of the extracts, by oral route. Two control groups were used in each experiment; one treated with quinine at low non-curative dose (10mg/ kg/ day, orally) and the other group was kept untreated. Each day from day 0 to 4, parasites were determined in coded blood smears by randomly counting 2000-6000 erythrocytes in the case of low parasitaemia ($\leq 10\%$) or up to 1000 erythrocytes in the case of higher parasitaemia. Overall mortality was monitored daily in all groups during a period of four weeks following inoculation. The inhibition of parasite growth in the drug-treated group was calculated. The extracts were considered partially active when parasitaemia was reduced by $> 30\%$.

Statistical analysis

The statistical significance of differences in mean parasitemias between control and test groups were assessed using the Student t-test. P-values of 0.05 or less were considered statistically significant.

Results and Discussion


The results of the 4-day suppressive antimalarial screening of the total extracts/pure compounds (and Quinine Hydrochloride) at different doses in mice parasitized with *P. berghei berghei* are summarised in Tables 1 and 2. The suppression of parasitemia expressed as percentage (S.P.; %) and standard deviations ($n = 5$) are given for each extract/drug.

Table 1: Mean chemosuppression of mice treated with total extracts

Treatment	Dose mg/kg/day	Mean (S.D) value %	
		Parasitemia	Chemosuppression
Control	saline	31.97 (5.83)	0.0 (0.0)
A	200	25.00 (0.57)	21.80 (1.77)
A2	200	27.30 (2.31)	14.61 (7.21)
M200	200	29.10 (2.69)	22.32 (1.79)
M800	800	18.07 (2.80)	43.49 (8.77)
Quinine Hydrochloride	10	3.03 (3.52)	90.51 (11.0)

Key: A : Dichloromethane Extract; A2 : 25% dichloromethane in methanol Extract
M200: Methanol Extract 200mg/kg/day; M800: Methanol Extract 800mg/kg/day

At 200 mg/kg the suppression of parasites was low: 21.80 % for dichloromethane extract, 14.6 % for 25 % dichloromethane in methanol extract, and 22.3 % for methanol extract. However, high dose for methanol extract (800 mg/kg), the percent of parasitemia suppression improved to 43.5 %. The three extracts had low antimalarial activities when compared to Quinine hydrochloride. The mean percentage parasitaemia in Quinine hydrochloride control group was 3.03 ± 3.52 %, while mean percentage parasitaemia in the untreated control was 31.97 ± 5.83 %. The progression of parasitemia is shown in Figure 2.


**Figure 2:** Progression of parasitemia with time after treatment with total extracts

The progression of parasitemia in animals treated with the pure compounds is shown in Figure 3. The antimalarial activity of total and pure compounds from *A. mellifera* in *P. berghei*-infected mice is shown in Tables 1 and 2 respectively. The *in vivo* test showed that the dichloromethane (CH_2Cl_2) in 50% methanol (MeOH) extract at a dose of 200mg/kg was inactive because there was no significant reduction in the chemosuppression of parasitaemia on the fourth day. However, the dichloromethane (CH_2Cl_2) and MeOH extracts at the same dose, produced chemosuppression of parasitemia (> 21.8% and 22.3 % respectively) when administered orally. At a dose of 800mg/kg, methanol extract produced the highest chemosuppression of parasitemia (> 43.5%) when administered orally. The profound chemosuppression of parasitemia of the methanol extract of this plant in our study underscores the need to study all parts of this plant such as roots and the leaves,

Table 2: Mean chemosuppression of mice treated with pure compounds.

Treatment	Dose mg/kg/day	Mean (S.D) value %	
		Parasitemia	Chemosuppression
Control	Water	36.70 (6.22)	0.0 (0.0)
ML 4	20	35.20 (7.41)	15.67 (3.27)
ML 9	20	30.60 (2.77)	16.50 (7.55)
ML 13	20	30.67 (2.77)	16.44 (7.56)
ML 11	20	37.03 (2.55)	00.82 (8.86)
ML 12	20	33.37 (10.49)	24.80 (12.33)
ML 14	20	33.87 (5.91)	16.62 (6.55)
Quinine Hydrochloride	10	04.85 (0.64)	86.79 (1.73)

Key: ML 4: Acetylated epicatechin (4 β -8) catechin; ML 9: 3-(Z)-*trans* coumaroylbetulin
 ML13: 3-(E)-*cis* coumaroylbetulin ; ML 11: 30-hydroxyl lupan-20 (29)-en -3-on
 ML 12 : Betulin; ML 14: Lupeol

**Figure 3:** Progression of parasitemia with time after treatment with pure compounds

which had been reported to be used also but not yet, documented.

The MeOH extract showed slight mortality rate at the dose of 800mg/kg weight of mice as compared to non-treated mice. This could be clear case of toxicity. The 3-(Z)-*trans*-coumaroylbetulin, lupeol and 3-(E)-*cis*-coumaroylbetulin were found to have close values of chemosuppression of parasitemia which was not significant. The parasitemia inhibition percent of betulin was the highest (24.8 %). This observation that betulin is not effective *in vivo* is consistent with earlier findings where it demonstrated *in vitro* inactivity at 500 mg/ml for both chloroquine resistant and sensitive *P. falciparum* [Steele et al, 1999]. However, the *in vivo* activity of betulin related triterpene; betulinic acid was ineffective at reducing parasitemia and also exhibited some toxicity [Steele et al, 1999]. On the

other hand, lupeol has been described to exhibit inhibitory activity on *Plasmodium falciparum* growth *in vitro* but lacks *in vivo* activity in mice infected with *P. berghei* (Alves et al., 1997). This result clearly indicated peculiarities in the metabolic disposition of the chemical constituents. Therefore, plants and pure compounds found to be active *in vitro* must be tested *in vivo* before a definite statement can be made on their antimalarial potential.

Acknowledgement

The authors gratefully acknowledge financial support from State Scholarships Foundation of Greece and study leave granted by Director KEMRI. This work is published with the approval of the Director KEMRI.

References

1. Adubofour, K. O. (1992). Drug resistance in malaria: A review of West African situation J. Natl. Med. Assoc, **84**:1025-1029.
2. Alves, T. M. A., Nagem, T. J., Carvalho, L. H. and Krettli, A.U. (1997). Antiplasmodial triterpene from *Vernonia brasiliensis*. Planta Med, **63**: 554-555
3. Bisset, B. C. and Nwaiwu, M. K. (1994). Quaternary alkaloids of *Tinospora* spp. Planta Medica, **48**: 275-279.
4. Daniel, H. I. and Molta, N. B. (1989). Efficacy of chloroquine in the treatment of malaria in children under the age of 5 years in Baissa (Gongola state), Nigeria. Annals. Trop. Med. Parasitol, 1989; **83**: 331-338.
5. Eltord, B. C. (1986). L-glutamine influx in malaria; infected erythrocytes; a target for antimalarials. Parasitology Today, **2**: 309-312.
6. Gessler, M. C., Msuya, D. E. and Nkunya, M. H. H. (1995). Traditional helars in Tanzania: The Treatment of malaria with plant remedies. J. Ethnopharmacol, **48**: 131-144.
7. Kokwaro, O. (1976). Medicinal plant of East Africa. East African Literature Bureau Kampala, Nairobi, Dar es Salaam
8. Krogstad, D. J., Schlesinger, P. L. and Herwaldt, B. L (1990). Antimalarial agents: Mechanism of chloroquine resistance. Antimicrob. Agents Chemother. **32**: 799-801.
9. Le Bras, J., Haitin, I., Bouree, P., Coco-cianci, O., Garin, J. P., Rey, M., Charmont, G. and Roue, R. (1986). Chloroquine-resistant *falciparum* in Benin. Lancet, **11**: 1043-1044.
10. Mahato, S. B., Nandy, A.K. and Roy, G. (1992). Triterpenoids. *Phytochemistry*, 1992; **31**: 2199-2249
11. Malan E. (1991). Derivatives of (+)-catechin-5-gallate from the bark of *Acacia nilotica*. *Phytochemistry* **30** (8): 2737-2739.
12. Mutai, C., Abatis, D., Vagias, C., Moreau, D., Roussakis, C. and Roussis, V. (2004). Cytotoxic lupane-type triterpenoids from *Acacia mellifera* *Phytochemistry*, **65**: 1159-1164.
13. Neequaye, J. and Coe-Ene, J. (1986). Taelman H. *In vivo* chloroquine resistant *falciparum* malaria in West Africa. Lancet, **1**: 153-154.
14. Peters, W. (1970). Techniques of Drug evaluation I; primary screening. In chemotherapy and drug resistance in malaria. Academic press 1970; London
15. Peter, W. (1982). Antimalarial drug resistance. British Medical Bulletin, **32**: 187-192.
16. Peters, W. (1998). Drug resistance in malaria parasites of animals and man. Adv. Parasitol, **41**: 1-62.
17. Sansonetti, P. J., Le Bras, C., Vedier, F., Charmont, G., Dupont, B. and Lepresle, C. (1985). Chloroquine-resistant *Plasmodium falciparum* in Cameroon. Lancet, 1985; **1**: 1154-1155.
18. Steele, J. C., Warhurst, D. C., Kirby, G.C. and Simmonds, M. S. (1999). *In vitro* and *In vivo* evaluation of betulinic acid as an antimalaria. *Phytother Res*, **13** (2): 115-119.
19. Warhurst, D. C. (2001). A molecular marker for chloroquine-resistant *falciparum* malaria (editorial). New Engl. J. Med, **344**: 299-302.
20. World Health Organisation (1984). WHO Advances in Malaria Chemotherapy. Technical Report Series No. 711.
21. Ziffer, H., Highet, R. J. and Klayman, D. L. (1997). Artemisinin; An endoperoxidic antimalarial from *Artemisia annua* L. *Prog. Chem. Org. Nat. Prod*, **72**: 123-214